News | June 04, 2022
Innate Pharma announces IPH5201 phase 2 study in lung cancer
Innate to receive $5M milestone payment from AstraZeneca
Innate to receive $5M milestone payment from AstraZeneca
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Subscribe To Our Newsletter & Stay Updated
